New flu shot contains adjuvant linked to Gulf War syndrome
A new version of the flu vaccine has the potential to create health problems far worse and longer lasting than a bout with the flu.
That’s because the new seasonal vaccine Fluad, made by Novartis Vaccines and Diagnostics Limited, contains the adjuvant MF59, which is directly related to Gulf War syndrome, suffered by Gulf War vets who were given anthrax vaccines during the first Gulf War. MF59 is added as an adjuvant because it has been shown to stimulate a greater immune response in those receiving vaccinations.
Symptoms of Gulf War syndrome include ulcers, arthritis, chronic diarrhea, fatigue and headaches, dizziness, fibromyalgia, memory loss, mood changes, multiple sclerosis, neuropsychiatric problems, rashes, skin lesions, photosensitive rashes and systemic lupus, according to osteopathic physician Joseph Mercola, M.D. A study by Tulane University researchers found that almost all veterans suffering from Gulf War syndrome tested positive for MF59 antibodies.
MF59 is an oil-in-water emulsion of squalene oil. According to The American Journal of Pathology, squalene is a cholesterol precursor which stimulates the immune system nonspecifically. One intradermal injection — or shot — of this adjuvant lipid can induce joint-specific inflammation in arthritis-prone rats.
MF59 was experimental at the time it was introduced into the anthrax vaccine and had not been approved by the Food and Drug Administration. In 2009, it began appearing in H1N1 vaccines made by GlaxoSmithKline and Novartis, even though it still had not been approved by the FDA for use in vaccines.
Now the FDA has approved MF59 for flu shots targeted at the elderly. I have long believed that the term “healthcare” is cover for euthanasia. Vaccines are a means of population control, and they are used to weed out the weak, infirm and elderly.
There are ways to avoid the flu while avoiding the flu shots.